Phibro Animal Health (NASDAQ:PAHC) Updates FY 2027 Earnings Guidance

Phibro Animal Health (NASDAQ:PAHC) updated its FY 2027 earnings guidance on Wednesday morning. The company provided EPS guidance of 3.410-3.590 for the period, compared to the consensus estimate of 3.340. The company issued revenue guidance of $1.6 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion.

Phibro Animal Health Trading Up 0.4%

PAHC stock traded up $0.16 during midday trading on Wednesday, reaching $36.09. 287,583 shares of the company traded hands, compared to its average volume of 295,650. The firm has a market capitalization of $1.46 billion, a price-to-earnings ratio of 15.49, a P/E/G ratio of 0.50 and a beta of 0.46. Phibro Animal Health has a 52-week low of $28.25 and a 52-week high of $60.08. The business has a 50 day moving average of $33.84 and a 200-day moving average of $42.54. The company has a debt-to-equity ratio of 1.97, a quick ratio of 1.26 and a current ratio of 3.17.

Phibro Animal Health (NASDAQ:PAHC) last released its earnings results on Wednesday, August 26th. The company reported $0.53 earnings per share for the quarter, missing the consensus estimate of $0.71 by ($0.18). The company had revenue of $396.75 million for the quarter, compared to the consensus estimate of $381.18 million. Phibro Animal Health had a net margin of 6.35% and a return on equity of 37.14%. Phibro Animal Health has set its FY 2027 guidance at 3.410-3.590 EPS. As a group, sell-side analysts expect that Phibro Animal Health will post 3.08 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Wednesday, September 2nd will be given a $0.12 dividend. This represents a $0.48 dividend on an annualized basis and a yield of 1.3%. The ex-dividend date of this dividend is Wednesday, September 2nd. Phibro Animal Health’s dividend payout ratio is 20.60%.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on PAHC. Weiss Ratings cut Phibro Animal Health from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, June 15th. Wall Street Zen downgraded Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citigroup lowered their target price on shares of Phibro Animal Health from $62.00 to $44.00 and set a “neutral” rating for the company in a research note on Thursday, May 14th. Finally, Zacks Research lowered shares of Phibro Animal Health from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 21st. One equities research analyst has rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $42.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. iSAM Funds UK Ltd bought a new position in shares of Phibro Animal Health during the third quarter valued at approximately $61,000. EverSource Wealth Advisors LLC raised its stake in Phibro Animal Health by 7,671.4% in the second quarter. EverSource Wealth Advisors LLC now owns 2,720 shares of the company’s stock worth $69,000 after buying an additional 2,685 shares in the last quarter. C M Bidwell & Associates Ltd. raised its stake in Phibro Animal Health by 1,756.5% in the fourth quarter. C M Bidwell & Associates Ltd. now owns 2,135 shares of the company’s stock worth $80,000 after buying an additional 2,020 shares in the last quarter. Advisory Services Network LLC purchased a new stake in Phibro Animal Health during the third quarter worth $96,000. Finally, Tower Research Capital LLC TRC increased its holdings in shares of Phibro Animal Health by 768.2% in the 2nd quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company’s stock valued at $118,000 after acquiring an additional 4,079 shares during the period. 99.34% of the stock is currently owned by institutional investors.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation (NASDAQ: PAHC) is a diversified global animal health and mineral nutrition company headquartered in Teaneck, New Jersey. The company develops, manufactures and markets a broad range of pharmaceutical, mineral nutrition and performance products designed to support the health and productivity of livestock, companion animals and aquaculture species. Phibro’s portfolio includes vaccines, anti-infective therapies, coccidiostats, disinfectants, premix minerals and specialty feed additives aimed at enhancing growth, immunity and overall animal well-being.

The company operates through three principal business segments: Animal Health, Mineral Nutrition and Performance Products.